E
Lisata Therapeutics, Inc.
LSTA
$1.95
-$0.0575-2.86%
E
Sell
3/21/2025Downgrade
Lisata Therapeutics, Inc. (LSTA) was downgraded to E+ from D- on 3/21/2025 due to a decline in the total return index and volatility index.
Lisata Therapeutics, Inc. (LSTA) was downgraded to E+ from D- on 3/21/2025 due to a decline in the total return index and volatility index.
D
Sell
3/6/2025Upgraded
Lisata Therapeutics, Inc. (LSTA) was upgraded to D- from E+ on 3/6/2025 due to an increase in the volatility index and total return index.
Lisata Therapeutics, Inc. (LSTA) was upgraded to D- from E+ on 3/6/2025 due to an increase in the volatility index and total return index.
E
Sell
2/13/2025Downgrade
Lisata Therapeutics, Inc. (LSTA) was downgraded to E+ from D- on 2/13/2025 due to a decline in the volatility index and total return index.
Lisata Therapeutics, Inc. (LSTA) was downgraded to E+ from D- on 2/13/2025 due to a decline in the volatility index and total return index.
D
Sell
1/28/2025Upgraded
Lisata Therapeutics, Inc. (LSTA) was upgraded to D- from E+ on 1/28/2025 due to an increase in the total return index and volatility index.
Lisata Therapeutics, Inc. (LSTA) was upgraded to D- from E+ on 1/28/2025 due to an increase in the total return index and volatility index.
E
Sell
1/7/2025Downgrade
Lisata Therapeutics, Inc. (LSTA) was downgraded to E+ from D- on 1/7/2025 due to a decline in the total return index, volatility index and growth index.
Lisata Therapeutics, Inc. (LSTA) was downgraded to E+ from D- on 1/7/2025 due to a decline in the total return index, volatility index and growth index.
D
Sell
10/25/2024Upgraded
Lisata Therapeutics, Inc. (LSTA) was upgraded to D- from E+ on 10/25/2024 due to an increase in the total return index and volatility index.
Lisata Therapeutics, Inc. (LSTA) was upgraded to D- from E+ on 10/25/2024 due to an increase in the total return index and volatility index.
E
Sell
10/10/2024Downgrade
Lisata Therapeutics, Inc. (LSTA) was downgraded to E+ from D- on 10/10/2024 due to a decline in the volatility index and solvency index.
Lisata Therapeutics, Inc. (LSTA) was downgraded to E+ from D- on 10/10/2024 due to a decline in the volatility index and solvency index.
D
Sell
6/21/2024Upgraded
Lisata Therapeutics, Inc. (LSTA) was upgraded to D- from E+ on 6/21/2024 due to an increase in the volatility index and total return index.
Lisata Therapeutics, Inc. (LSTA) was upgraded to D- from E+ on 6/21/2024 due to an increase in the volatility index and total return index.
E
Sell
6/6/2024Downgrade
Lisata Therapeutics, Inc. (LSTA) was downgraded to E+ from D- on 6/6/2024 due to a decline in the growth index, volatility index and solvency index. Operating cash flow declined 72.7% from -$4.07M to -$7.03M, and EBIT declined 9.56% from -$6.03M to -$6.6M.
Lisata Therapeutics, Inc. (LSTA) was downgraded to E+ from D- on 6/6/2024 due to a decline in the growth index, volatility index and solvency index. Operating cash flow declined 72.7% from -$4.07M to -$7.03M, and EBIT declined 9.56% from -$6.03M to -$6.6M.
D
Sell
5/20/2024Upgraded
Lisata Therapeutics, Inc. (LSTA) was upgraded to D- from E+ on 5/20/2024 due to an increase in the growth index, volatility index and total return index.
Lisata Therapeutics, Inc. (LSTA) was upgraded to D- from E+ on 5/20/2024 due to an increase in the growth index, volatility index and total return index.
E
Sell
1/4/2023Downgrade
Lisata Therapeutics, Inc. (LSTA) was downgraded to E+ from D- on 1/4/2023 due to a decline in the volatility index and total return index.
Lisata Therapeutics, Inc. (LSTA) was downgraded to E+ from D- on 1/4/2023 due to a decline in the volatility index and total return index.
D
Sell
5/31/2022Upgraded
Caladrius Biosciences, Inc. (CLBS) was upgraded to D- from E+ on 5/31/2022 due to an increase in the volatility index.
Caladrius Biosciences, Inc. (CLBS) was upgraded to D- from E+ on 5/31/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Caladrius Biosciences, Inc. (CLBS) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index, growth index and total return index. Operating cash flow declined 22.55% from -$4.6M to -$5.64M.
Caladrius Biosciences, Inc. (CLBS) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index, growth index and total return index. Operating cash flow declined 22.55% from -$4.6M to -$5.64M.
D
Sell
5/5/2022Upgraded
Caladrius Biosciences, Inc. (CLBS) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index and growth index.
Caladrius Biosciences, Inc. (CLBS) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index and growth index.
E
Sell
4/20/2022Downgrade
Caladrius Biosciences, Inc. (CLBS) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index, volatility index and total return index.
Caladrius Biosciences, Inc. (CLBS) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index, volatility index and total return index.
D
Sell
11/8/2021Downgrade
Caladrius Biosciences, Inc. (CLBS) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index, total return index and volatility index.
Caladrius Biosciences, Inc. (CLBS) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index, total return index and volatility index.
D
Sell
3/3/2021Upgraded
Caladrius Biosciences, Inc. (CLBS) was upgraded to D from D- on 3/3/2021 due to a major increase in the growth index, total return index and solvency index. The quick ratio increased from 9.63 to 9.86, and earnings per share increased from -$0.2864 to -$0.28.
Caladrius Biosciences, Inc. (CLBS) was upgraded to D from D- on 3/3/2021 due to a major increase in the growth index, total return index and solvency index. The quick ratio increased from 9.63 to 9.86, and earnings per share increased from -$0.2864 to -$0.28.
D
Sell
11/10/2020Downgrade
Caladrius Biosciences, Inc. (CLBS) was downgraded to D- from D on 11/10/2020 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 178.13% from $4.5M to -$3.52M, earnings per share declined from $0.5017 to -$0.29, and EBIT declined 24.65% from -$4.29M to -$5.35M.
Caladrius Biosciences, Inc. (CLBS) was downgraded to D- from D on 11/10/2020 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 178.13% from $4.5M to -$3.52M, earnings per share declined from $0.5017 to -$0.29, and EBIT declined 24.65% from -$4.29M to -$5.35M.
D
Sell
5/1/2020Upgraded
Caladrius Biosciences, Inc. (CLBS) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index.
Caladrius Biosciences, Inc. (CLBS) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index.
D
Sell
8/14/2018Downgrade
Caladrius Biosciences, Inc. (CLBS) was downgraded to D- from D+ on 8/14/2018 due to a significant decline in the valuation index, efficiency index and growth index. Total capital declined 4.22% from $45.41M to $43.49M.
Caladrius Biosciences, Inc. (CLBS) was downgraded to D- from D+ on 8/14/2018 due to a significant decline in the valuation index, efficiency index and growth index. Total capital declined 4.22% from $45.41M to $43.49M.
D
Sell
6/19/2018Upgraded
Caladrius Biosciences, Inc. (CLBS) was upgraded to D+ from D on 6/19/2018 due to a noticeable increase in the volatility index, total return index and efficiency index.
Caladrius Biosciences, Inc. (CLBS) was upgraded to D+ from D on 6/19/2018 due to a noticeable increase in the volatility index, total return index and efficiency index.
D
Sell
8/11/2017Upgraded
Caladrius Biosciences, Inc. (CLBS) was upgraded to D from D- on 8/11/2017 due to a significant increase in the valuation index, efficiency index and solvency index. The quick ratio increased from 0.65 to 4.1, net income increased 513.67% from -$9.36M to $38.72M, and total capital increased 132.02% from $23.55M to $54.64M.
Caladrius Biosciences, Inc. (CLBS) was upgraded to D from D- on 8/11/2017 due to a significant increase in the valuation index, efficiency index and solvency index. The quick ratio increased from 0.65 to 4.1, net income increased 513.67% from -$9.36M to $38.72M, and total capital increased 132.02% from $23.55M to $54.64M.
D
Sell
5/17/2017Upgraded
Caladrius Biosciences, Inc. (CLBS) was upgraded to D- from E+ on 5/17/2017 due to an increase in the valuation index, total return index and volatility index.
Caladrius Biosciences, Inc. (CLBS) was upgraded to D- from E+ on 5/17/2017 due to an increase in the valuation index, total return index and volatility index.
E
Sell
7/27/2016Downgrade
Caladrius Biosciences, Inc. (CLBS) was downgraded to E+ from D- on 7/27/2016 due to a decline in the solvency index and valuation index. Debt to equity increased from 0.71 to 0.97.
Caladrius Biosciences, Inc. (CLBS) was downgraded to E+ from D- on 7/27/2016 due to a decline in the solvency index and valuation index. Debt to equity increased from 0.71 to 0.97.
D
Sell
3/11/2016Downgrade
Caladrius Biosciences, Inc. (CLBS) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index, total return index and efficiency index. Total capital declined 13.56% from $83.09M to $71.82M.
Caladrius Biosciences, Inc. (CLBS) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index, total return index and efficiency index. Total capital declined 13.56% from $83.09M to $71.82M.
NASDAQ
04/10/2025 3:53PM Eastern
Quotes delayed
